4-(N,N-Dimethyl-carbamoyl)-4-phenyl-piperidin | 2525-32-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(N,N-Dimethyl-carbamoyl)-4-phenyl-piperidin
• 英文别名: 4-(N,N-dimethylaminocarbonyl)-4-phenylpiperidine；4-(N,N-Dimethylcarbamoyl)-4-phenylpiperidine；4-phenyl-piperidine-4-carboxylic acid dimethylamide；N,N-dimethyl-4-phenylpiperidine-4-carboxamide
• CAS: 2525-32-8
• 化学式: C₁₄H₂₀N₂O
• 分子量: 232.326
• InChiKey: JJZKYGDMIZQQAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Cyclohexanecarboxylic acid, 2,2-dimethyl-4-oxo-, (1R)- 、 4-(N,N-Dimethyl-carbamoyl)-4-phenyl-piperidin 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 氯仿 为溶剂， 反应 12.0h， 生成
  参考文献：
  名称：

  Design, synthesis and evaluation of a novel cyclohexanamine class of neuropeptide Y Y1 receptor antagonists

  摘要：

  A novel series of cyclohexanamine derivatives was designed and synthesized as potent and selective human neuropeptide Y Y1 receptor antagonists. Modification of high-throughput screening hit compound 1 resulted in the identification of compound 3i, which displays potent Y1 activity and good selectivity towards hERG K(+) channel and serotonin transporter. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.06.050
• 作为产物：
  描述：

  1-tert-butoxycarbonyl-4-phenyl-piperidine-4-carboxylic acid dimethyl-amide 在 2,6-二甲基吡啶 、 三氟甲磺酸三甲基硅酯 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 4-(N,N-Dimethyl-carbamoyl)-4-phenyl-piperidin
  参考文献：
  名称：

  Design, synthesis and evaluation of a novel cyclohexanamine class of neuropeptide Y Y1 receptor antagonists

  摘要：

  A novel series of cyclohexanamine derivatives was designed and synthesized as potent and selective human neuropeptide Y Y1 receptor antagonists. Modification of high-throughput screening hit compound 1 resulted in the identification of compound 3i, which displays potent Y1 activity and good selectivity towards hERG K(+) channel and serotonin transporter. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.06.050

文献信息

• 4,4-Disubstitued piperidines, and methods of use thereof
  申请人：——

  公开号：US20020177607A1

  公开（公告）日：2002-11-28

  One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

  本发明的一个方面涉及杂环化合物。本发明的第二个方面涉及将这些杂环化合物用作各种哺乳动物细胞受体的配体，包括多巴胺转运体。本发明的化合物将用于治疗许多影响哺乳动物的疾病、状况和疾病，包括但不限于成瘾、焦虑、抑郁、性功能障碍、高血压、偏头痛、阿尔茨海默病、肥胖症、呕吐、精神病、镇痛、精神分裂症、帕金森病、不宁腿综合症、睡眠障碍、注意力缺陷多动症、肠易激综合症、早泄、月经不适综合症、尿失禁、炎性疼痛、神经病性疼痛、Lesche-Nyhane病、威尔逊病和抽动症。本发明的另一个方面涉及合成这些杂环化合物的组合库，并对这些库进行生物活性筛选，例如在基于多巴胺转运体的测定中。
• Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them
  申请人：——

  公开号：US20040220223A1

  公开（公告）日：2004-11-04

  Compounds of formula (I), a method for obtaining them and pharmaceutical compositions containing them are described. The compounds are useful as human NK 3 receptor antagonists.

  本文描述了化学式（I）的化合物，获得它们的方法以及含有它们的药物组合物。这些化合物可用作人类NK3受体拮抗剂。
• 4,4-disubstituted piperidines, and methods of use thereof
  申请人：——

  公开号：US20040142974A1

  公开（公告）日：2004-07-22

  One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

  本发明的一个方面涉及杂环化合物。本发明的第二方面涉及将杂环化合物用作各种哺乳动物细胞受体的配体，包括多巴胺转运体。本发明的化合物将用于治疗许多困扰哺乳动物的疾病，病症和疾病，包括但不限于成瘾，焦虑，抑郁，性功能障碍，高血压，偏头痛，阿尔茨海默病，肥胖症，呕吐，精神病，镇痛，精神分裂症，帕金森病，不宁腿综合症，睡眠障碍，注意力不足多动症，肠易激综合症，早泄，月经困扰综合症，尿失禁，炎症性疼痛，神经痛，Lesche-Nyhane病，威尔逊病和抽动症。本发明的另一个方面涉及合成杂环化合物的组合库，并对这些库进行生物活性筛选，例如基于多巴胺转运体的测定。
• 4,4-Disubstituted piperidines, and methods of use thereof
  申请人：Hoemann Z. Michael

  公开号：US20070225331A1

  公开（公告）日：2007-09-27

  One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

  本发明的一个方面涉及杂环化合物。本发明的另一个方面涉及将这些杂环化合物用作各种哺乳动物细胞受体的配体，包括多巴胺转运体。本发明的化合物将用于治疗许多影响哺乳动物的疾病、病症和疾病，包括但不限于成瘾、焦虑、抑郁、性功能障碍、高血压、偏头痛、阿尔茨海默病、肥胖症、呕吐、精神病、镇痛、精神分裂症、帕金森病、不宁腿综合症、睡眠障碍、注意力缺陷多动症、肠易激综合症、早泄、月经困扰综合症、尿失禁、炎症性疼痛、神经病性疼痛、Lesche-Nyhane病、威尔逊病和托瑞特综合症。本发明的另一个方面涉及合成这些杂环化合物的组合库，以及筛选这些库的生物活性，例如在基于多巴胺转运体的测定中。
• Human NK.sub.3 receptor-selective antagonist compounds, method for
  申请人：Sanofi-Synthelabo

  公开号：US06028082A1

  公开（公告）日：2000-02-22

  Compounds of formula (I), a method for obtaining them and pharmaceutical compositions containing them are described. The compounds are useful as human NK.sub.3 receptor antagonists.

  本发明涉及一种化合物(I)、其制备方法以及含有该化合物的制药组合物。该化合物可用作人类NK.sub.3受体拮抗剂。